ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 414

First-Degree Relatives without Rheumatoid Arthritis Exhibit Reactivity to Multiple Anti-Citrullinated Protein Antibodies in Association with Rheumatoid Arthritis-Related Clinical Characteristics: Studies of the Etiology of Rheumatoid Arthritis

Kendra A. Young1, Kevin D. Deane2, Lezlie A. Derber3, Jan M. Hughes-Austin4, Michael H. Weisman5, Jane H. Buckner6, Ted R. Mikuls7, James R. O'Dell8, Richard M. Keating9, Peter K. Gregersen10, V. Michael Holers11 and Jill M. Norris1, 1Epidemiology, Colorado School of Public Health, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, 4Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 5Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 6Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, 9Rheumatology Section, The University of Chicago, Chicago, IL, 10Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 11Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), auto-immunity and rheumatoid arthritis, pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Prior to diagnosis of rheumatoid arthritis (RA), there are increases in the number of citrullinated proteins that anti-citrullinated protein antibodies (ACPA) target, suggesting an expansion of autoimmunity in early RA development that, if fully understood, may provide insight into the earliest antigenic targets important in disease pathogenesis. Anti-CCP assays are currently the most widely used ACPA assessments; however, the specific epitopes recognized by these commercial assays are unknown, thereby limiting the ability to make inferences about the type and expansion of ACPA responses. Our objective was to utilize multiplex technology to examine ACPA reactivity to specific citrullinated proteins and peptides in the pre-diagnosis period of RA development by performing this analysis in first-degree relatives (FDRs) of RA probands, who do not have RA, but are at increased risk of future RA.

Methods:

We selected 113 FDRs (Ab+) who had been positive at ≥1 research visit for any of 5 Ab:  rheumatoid factor (RF) by nephelometry; RF by ELISA for isotypes IgM, IgG, or IgA; or anti-CCP2; and 100 FDRs (Ab-) who had never been autoantibody positive.  A panel of 18 ACPA was measured using a bead-based assay in serum from 397 visits by these FDRs.  Cut-offs for positivity for each ACPA were determined using receiver operating characteristic (ROC) curves of data from 200 patients with established RA (1987 ACR criteria), and 98 blood-bank controls, where we found that positivity for ≥ 9 ACPAs had 67% sensitivity and 92% specificity for RA, comparable to the 70% sensitivity and >95% specificity for anti-CCP2.  In FDRs, we examined reactivity to ACPA and associations between ACPA (number positive and positivity for ≥ 9 ACPA) and RA-related characteristics including positivity for RF (nephelometry or isotypes) and swollen or tender joints on exam.  While we had too few anti-CCP2 positive FDRs to test (n=8), associations were examined with the high-risk autoantibody profile (i.e., anti-CCP2 and/or ≥2 RF isotypes), which was shown to be highly specific (>96%) for future RA. 

Results: Both Ab+ and Ab- FDRs showed reactivity to multiple ACPA, although Ab+ FDRs were positive for a greater number of ACPA than Ab- FDRs (mean 3.1 ± 4.3 vs. 2.1 ± 2.8, p=0.04).  Of the 8 anti-CCP2 positive FDRs, 5 were positive for at least 9 ACPA, and 4 were positive for 16 or more ACPA.  76% of anti-CCP2 negative FDRs were positive for ≤ 2 ACPA, and 10% were positive ≥ 9 ACPA. Being positive for a greater number of ACPA is associated with being positive for RF (OR=1.22, 95%CI 1.09-1.35), with the IgM (OR=1.17, 95% CI 1.00-1.3) and IgA (OR=1.14, 95% CI 1.02-1.28) RF isotypes, and for those positive for anti-CCP2 and/or ≥2 RF isotypes (OR=1.22, 95%CI 1.09-1.35).  FDRs positive for at least 9 ACPA had significantly greater odds of having least one tender joint on exam (OR=7.59, 95% CI 1.97-29.25). A similar association was observed for increasing number of ACPA (OR=1.21, 95% CI 1.05-1.39).    

Conclusion: These results indicate that there may be RA-related autoimmunity and even early inflammatory arthritis in FDRs without 1987 ACR classified RA, even in FDRs negative for RF and anti-CCP2.  Prospective follow-up is needed to further asses these findings.


Disclosure:

K. A. Young,
None;

K. D. Deane,
None;

L. A. Derber,
None;

J. M. Hughes-Austin,
None;

M. H. Weisman,
None;

J. H. Buckner,
None;

T. R. Mikuls,
None;

J. R. O’Dell,
None;

R. M. Keating,
None;

P. K. Gregersen,
None;

V. M. Holers,
None;

J. M. Norris,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/first-degree-relatives-without-rheumatoid-arthritis-exhibit-reactivity-to-multiple-anti-citrullinated-protein-antibodies-in-association-with-rheumatoid-arthritis-related-clinical-characteristics-stud/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology